The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.c

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

Publications

Lind JS, Smit EF, Grünberg K, Senan S, Lagerwaard FJ

Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(9):1050-3

Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, Marquette CH

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

BMC cancer. 2007;7:150

Yoneda KY, Shelton DK, Beckett LA, Gandara DR

Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(6):537-43